Governor Martin O’Malley today announced appointments to the Maryland Council for Educator Effectiveness; the University System of Maryland Board of Regents; the Blue Ribbon Commission on Transportation Funding; the State Health Services Cost Review Commission; and the Task Force to Study Nanobiotechnology.
“I am proud to announce the appointments to the various Boards and Commissions across the State. Each appointee brings a wealth of knowledge and expertise that will serve as an asset to the Boards they will serve on,” said Governor O’Malley. “We have worked hard to compile a list of individuals from across our State with diverse educational, career, geographic, gender and ethnic backgrounds to continue to help protect Maryland’s priorities.”
Among the list of professionals appointed by the governor as members of the Task Force to Study Nanobiotechnology is Dr. Patrick Lu, Founder, President and CEO of Sirnaomics, Inc., a biopharmaceutical company focusing on Nanoparticle-Enhanced RNAi technology for drug discovery and targeted therapeutics. Dr. Lu received his Ph.D. in Life Sciences from Sun Yat-sen University in Guangzhou, China and his postdoctoral training at the University of Maryland at College Park and Georgetown University Medical School. He is a resident of Montgomery County.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors and corporate partnerships. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.